Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta

Launched by THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · Jun 17, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the best time to plan a cesarean delivery for pregnant women who have a condition called placenta previa with placenta accreta. These conditions can cause serious bleeding before or during delivery. Currently, doctors usually recommend scheduling a cesarean between 34 and 37 weeks of pregnancy, but it’s not clear whether delivering at 37 weeks or earlier at 36 weeks is safer for both the mother and baby. This study aims to find out if waiting until 37 weeks to deliver can help newborns be more mature without increasing the risk of heavy bleeding or emergency surgery for the mother.

Women who are between 28 and 34 weeks pregnant, have been diagnosed with placenta previa and accreta through ultrasound and MRI scans, and are planning to have a cesarean delivery at one of the study hospitals may be eligible to join. Women with multiple pregnancies, other serious pregnancy complications, or certain health problems won’t be able to participate. If they take part, women will be randomly assigned to have their cesarean planned either at 36 weeks or at 37 weeks. The study will then compare how both mothers and babies do after delivery to see which timing is safer and better for health. This trial is not yet recruiting participants but hopes to provide clearer guidance for managing this high-risk pregnancy condition.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 28-34 weeks of gestation.
• • Both ultrasound and MRI indicate placenta previa with placenta accreta spectrum (PAS).
• • Planned to undergo cesarean delivery at the participating study hospitals.
• • Agree to participate and sign the informed consent form.
• Exclusion Criteria:
• • Multiple gestation.
• • Other obstetric complications (e.g., preeclampsia, vasa previa), and severe maternal medical conditions (e.g., uncontrolled diabetes, progressive cardiovascular disease, active systemic lupus erythematosus, liver cirrhosis).
• • Major uterine structural anomalies (e.g., uterine didelphys, Uterine tumors ≥5 cm).
• • Estimated fetal weight \<3rd percentile for gestational age, major congenital anomalies, intrauterine fetal demise.